February 20, 2018 The total follow-up period was 1341 person-years . The overall study retention rate was 94.8 percent. Additional information on the CAPRISA 004 trial have been published previously6,13,14; see also the analysis protocol, available with the full text of this content at NEJM.org. All women were followed up regular with risk-reduction counseling, provision of condoms, pregnancy assessment and contraception provision, medical assessments, and safety assessments. At each monthly study visit, females were requested to return all used and unused applicators for an assessment of adherence.. Abbott Reports 16.1 Percent Sales Development in Fourth Quarter Abbott today announced financial results for the fourth quarter ended Dec. 31, 2007. Worldwide product sales in the fourth one fourth elevated 16.1 % to $7.2 billion, including a favorable 4.5 % aftereffect of exchange rates. For the full-year 2007, worldwide product sales improved 15.3 % to $25.9 billion, including a favorable 3.2 % effect of exchange rates. U.S. Pharmaceutical sales increased 16.6 % and international pharmaceutical sales increased 21.3 %, driven by double-digit growth in HUMIRA, Kaletra and TriCor, and including $179 million of Niaspan product sales. HUMIRA attained full-year worldwide sales in excess of $3 billion in 2007 and the company forecasts global sales for HUMIRA of approximately $4 billion in 2008.